Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of oral BKM120 as second-line treatment for advanced endometrial carcinoma
2010-022015-19Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of buparlisib in endometrial cancer (EC), sponsored by Novartis. Primary endpoint: Objective response rate in patients with PI3K pathway activation. Started Dec 2010; status: terminated.
02
Drugs
buparlisib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2010-022015-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022015-19.